CGBio, specializing in bio regenerative medicine (CEO Hyun Seung Yu), announced on the 15th their recent participation in Global Spine Congress 2023 (hereinafter the “GSC2023”), an international spine conference held in Prague, Czech.
The GSC 2023 is one of the world’s top three prestigious academic conferences, attracting around 2,000 renowned spine specialists from all around the world. It serves as a platform for sharing authoritative lectures, clinical experiences and research findings in the field of spine.
At the GSC 2023, CGBio showcased their flagship products in the field of spine such as NOVOSIS, NOVOMAX, and Excender.
NOVOSIS, the first bio fusion medical device in the country, is a bone substitute that incorporates hydroxyapatite (HA) carrier loaded with bone generative protein rhBMP-2. NOVOMAX, a spine disc spacer that is directly combined with bones using bio new material BSG-7, features high biocompatibility compared to existing artificial bones. Excender, a height extended cage, is designed to grow in height after insertion into the body, creating space for the injection of a bone substitute. It is structurally enclosed to minimize the risk of loss of the injected bone substitute.
Professor Jeffrey Wang from Keck Medical Center of USC led the conference, and professor Ram Kiran Alluri, professor Kim Ho-joong from Seould National University Hospital in Bundang, and professor Kim Jin-sung from Seoul St. Mary’s Hospital delivered lectures on the topic of “alternative of bone grafting”.
Professor Ram Kiran Alluri presented on the limitations of collagen sponge-based bone substitute currently used in the US, suggesting that NOVOSIS, a bone substitute using the HA, could be a new alternative. Professor Kim Ho-joong then presented on clinical experiences where NOVOSIS was employed to address the limitations pointed out by professor Alluri, attracting significant attention among the attendees.
Subsequently, professor Kim Jin-sung shared his experiences using NOVOMAX, a next-generation cervical cage made of osteo-active bioglass initially developed by CGBio, for bone implantation. Professor Kim Jin-sung said, “NOVOMAX shows a high rate of bone fusion without requiring extra bone grafting, including bone substitutes, and exhibits a significantly low incidence of abnormal reaction”
After the presentations, attendees from various countries flocked to the CGBio’s promotion booth, making purchases on-site or expressing keen interest in collaborating on clinical studies. Furthermore, business meetings were arranged with medical device distribution companies in Italy, Hungary, Chile and Mexico for product supply.
Jeong Hyo-cheol, head of Bone Spine Business Department, said, “At the GSC2023, we showcased our products to spine specialists worldwide and reaffirmed the significance of ongoing development in the field of spine medical devices and its impact on treatment outcomes.”, adding “As a company with extensive expertise in spine, we will continue to research and develop new products, as well as foster collaborations with esteemed medical professionals worldwide to enhance the overall spine treatment landscape”.
▲ CGBio showcases next-generation spine solutions at one of the world’s top three spine conferences
▲ CGBio showcases next-generation spine solutions at one of the world’s top three spine conferences
